Uncategorized

Cellares extends funding for cell therapy manufacturing 

Published

on

""

Cellares has raised $327 million for its cell therapy infrastructure project. 

Cellares, which says it is the first Integrated Development and Manufacturing Organization (IDMO), extended its Series D funding thanks to an additional $50 million investment from Prime Radiant Partners. 

The investment is set to support the next phase of Cellares’ global Smart Factory buildout. The organisation’s European manufacturing facility, under construction in Leiden, The Netherlands, is designed to serve drug sponsors across global markets with the same automated manufacturing infrastructure available in the United States and will be GMP-ready in 2027.  

“A global cell therapy manufacturing network has to be built in all major markets at once,” said Fabian Gerlinghaus, Co-Founder and CEO of Cellares.  

“Prime Radiant’s operational depth in pharma services across continental Europe makes them a strategic partner as we expand our manufacturing presence in Europe.  

“The investors who have joined this Series D reflect the strength of the platform and the scale of what comes next.” 

 

The post Cellares extends funding for cell therapy manufacturing  appeared first on Drug Discovery World (DDW).

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version